Breaking down the barriers: fMRI applications in pain, analgesia and analgesics

This review summarizes functional magnetic resonance imaging (fMRI) findings that have informed our current understanding of pain, analgesia and related phenomena, and discusses the potential role of fMRI in improved therapeutic approaches to pain. It is divided into 3 main sections: (1) fMRI studies of acute and chronic pain. Physiological studies of pain have found numerous regions of the brain to be involved in the interpretation of the 'pain experience'; studies in chronic pain conditions have identified a significant CNS component; and fMRI studies of surrogate models of chronic pain are also being used to further this understanding. (2) fMRI studies of endogenous pain processing including placebo, empathy, attention or cognitive modulation of pain. (3) The use of fMRI to evaluate the effects of analgesics on brain function in acute and chronic pain. fMRI has already provided novel insights into the neurobiology of pain. These insights should significantly advance therapeutic approaches to chronic pain.


Background: 'O (Chronic) Pain Miserum'
At least two major hurdles remain in the treatment of chronic pain. The first is that no objective test for pain currently exists. A blood test, genetic marker or psychophysical measure would greatly improve diagnosis of chronic pain. The second is the lack of an "antibiotic equivalent" (i.e., drugs with high sensitivity and specificity) for the treatment of chronic pain subtypes (e.g., neuropathic pain). Controlled trials of drug efficacy indicate that, on average, the most effective drugs of different classes have similar efficacy (around 30% greater than placebo) across neuropathic conditions [1][2][3]. Analgesic use is dictated by both efficacy and adverse side effects and side effects can sometimes take precedence over efficacy [4]. A lack of controlled trials for other methods of pain treatment (interventional, psychological, physical therapy) makes it difficult for physicians to evaluate these possible thera-pies. As a result, chronic pain treatment is difficult, and physicians and patients often resort to using multiple treatments simultaneously or sequentially in the effort to achieve pain relief. Unfortunately, even a combined therapeutic approach frequently offers little benefit ( Figure 1).
Recent advances in functional imaging have revolutionized our concept of central process of pain. Indeed, it seems that we are on the verge of using this technology to reach a fundamental new understanding of clinical pain, particularly chronic pain (defined as pain lasting for more than 6 months). Subdivision of chronic pain syndromes into chronic neuropathic pain (e.g., phantom pain, postherpetic neuralgia), chronic nociceptive pain (e.g., arthritis, migraine), and a group comprising very poorly understood categories of pain (e.g., fibromyalgia, depressioninduced pain, or complex regional pain syndrome) has not clarified mechanistic processes. Even classification of chronic pain types based on clinical disease (e.g., cancer pain, diabetic pain) has not proved very helpful in understanding the mechanisms underlying chronic pain. Recently a mechanistic approach to defining pain has been suggested in which specific pain phenotypes such as shooting pain, burning pain, and allodynia can be applied across pain types such as neuropathic pain. [5]. However, this approach is based primarily on an understanding of peripheral nerve and spinal cord processing. Functional imaging has already redefined chronic pain as a degenerative disease, and has shed some light on complex diseases such as fibromyalgia [6]. Since brain responses are the final common pathway in behavioral responses to pain (unconscious and conscious), we believe that the application of functional imaging will allow us to categorize pain conditions in an objective manner and to better understand the underlying circuitry and identify targets for a new generation of analgesics [7,8]. fMRI measures neural activity by an indirect evaluation of changes in blood flow in capillary beds [9]. A number of approaches including block design [10], event-related [11], and percept-related. [12] paradigms, have been applied to fMRI studies of physiological, clinical and pharmacological aspects of pain and analgesia. Application of baseline measures of spontaneous pain have allowed the "basal state" to be evaluated.) [13]. Issues per-taining to the validity of fMRI in pain and analgesic measures have been presented elsewhere [14].
"To consider only the sensory features of pain, and ignore its motivational and affective properties, is to look at only part of the problem, not even the most important part at that." This statement of Melzack and Casey's [15] was an early recognition of these aspects of pain, but their importance is now widely accepted. The ability to use fMRI to image the whole brain at the same time and to use powerful algorithms to segregate functional circuits allows us to begin to elucidate the CNS processes underlying affective and motivational components of pain. It also allows a broader window to observe potential CNS sites of drug action. Our understanding of 'difficult' disease states (e.g., fibromyalgia or depression-related pain), the placebo response, emotional responses (e.g., empathy), and acupuncture will clearly be influenced by new insights into how emotional circuitry in the brain functions in pain states and in responses to analgesics. [16]. In this paper, we review the contribution of fMRI to the understanding of acute and chronic pain, its use in surrogate models and for evaluation of endogenous pain systems including the placebo response, and its potential use as an objective measure of analgesic efficacy. The approach we have taken to summarize the new advances has been to provide an overview for each domain (e.g., Acute and Chronic pain, Endogenous Systems etc.) and summary tables that focus on specific areas within each domain (e.g., Chronic pain: The problem with chronic pain Figure 1 The problem with chronic pain. Therapy for acute pain (e.g., acute inflammation, trauma, post-surgical pain) is overall excellent. However, in chronic pain (e.g., neuropathic pain, fibromyalgia, complex regional pain syndrome), therapy is poor. This group thus falls into a zone (circles) of "therapeutic failure" or "therapeutic impasse" where multiple therapies are tried with overall little success. Functional imaging appears poised to open up new approaches to the understanding of chronic pain conditions. An improved basic understanding of the mechanisms underlying chronic pain is likely to suggest new avenues for the development of novel pharmacotherapies.

Drug Efficacy
Pain Acute Pain with good drug treatment outcomes Chronic Pain with poor drug treatment outcomes Neuropathic, Fibromyalgia etc.). Studies listed are predominantly from peer-reviewed journals (Data Sources: Medline) or data from our own lab presented at Society for Neuroscience and/or in press. We attempted to include primary examples on specific entities of CNS processing as defined with fMRI that are related to pain, analgesia and analgesics.

Advancing our Understanding of CNS Mechanisms in Acute and Chronic Pain through fMRI
fMRI of Physiological Pain -a new understanding of brain regionsinvolved in pain processing in humans Much of the work in fMRI of pain has utilized thermal stimuli (contact peltier thermodes or laser) to activate pain circuits. Other types of stimuli, including electrical and mechanical (pressure) have not been as extensively used either in the intact system or where sensitization has been experimentally induced (see Table 3). The accumulation of data has begun to identify brain regions involved in pain processing -from peripheral ganglia to central limbic and brainstem structures previously only implicated in animal studies in the preclinical literature (see Table 1).
Some of these regions are part of well-defined pain circuits (e.g., PAG, parabrachial nuclei) while for others such as the nucleus accumbens, their specific role in pain processing is not well understood [17,18]. Studies have reported specificity of somatotopic organization of structures outside of the primary somatosensory cortex involved in pain processing in humans; these such as the insula [19] and the trigeminal system [14,20]. Indeed, the results of human imaging help focus attention on specific regions, including the nucleus accumbens (involved in emotional salience), the insula (involved in specific interpretation of noxious stimuli) or the amygdala (involved in fear), opening new vistas for understanding how the human brain evaluates pain. The ability to evaluate activity and organize active regions into neural circuits that subserve specific pain/analgesia functions (i.e., sensory, emotional, autonomic, endogenous analgesic circuits) is a step forward. A number of studies have already begun this task including segregation of function within a structure (e.g., PAG [17] and NAc [18]), defining analgesia as a rewarding process [21], and functional differentiation of activation sites within a particular brain region (e.g., cognitive and affective regions within the anterior cingulate [17]).
What is needed now is to further evaluate these brain areas, some of whose role is newly defined in pain processing in humans, at a functional level. Several new fMRI approaches will aid this effort including techniques that allow definition of large scale systems organization [22]; techniques that define circuits/functional connectivity [23]; and automated parcellation of brain structures [24,25] including the thalamus [26]. Imaging studies have not only unveiled new regions involved in pain processing, but have also contributed new insights into the functioning of these regions in experimental pain. For example, the hippocampus, classically associated with memory, has been shown to be involved in pain-induced anxiety [27][28][29].

fMRI of Chronic Pain
Imaging clinical conditions is fraught with issues that make it more challenging, including the fact that it is difficult to assemble a cohort with similar symptoms, duration of disease, medication history, age distribution, etc. Among clinical conditions, chronic pain has a particularly wide spectrum of patient presentations and medical histories. However, studies have begun to evaluate CNS changes that occur in patients with chronic pain (see review by Apkarian and colleagues [30]), including those with neuropathic pain, fibromyalgia, complex regional pain syndrome and visceral pain ( Table 2).
A number of important issues are emerging in the evaluation of chronic pain conditions as fMRI and associated imaging technologies become more sophisticated. Chronic pain produces changes that become manifest as alterations in the central nervous system. One may term this "centralization of hyperalgesia" or "centralization of pain". This has been evaluated across diseases including fibromyalgia [6], chronic back pain [31], and irritable bowel syndrome [32]. During functional imaging of fibromyalgia and chronic back pain, enhanced responses to thermal or mechanical stimuli that are applied heterotopically (i.e., away from the actual location of the pain) are present in a number of CNS regions, including nonsensory regions. Differences in specific responses to brush, heat and cold in affected vs. intact regions in patients with neuropathic pain have also been reported [33]. One feature that seems to be of in common with chronic pain patients is significantly greater frontal lobe activation in chronic pain sufferers [30]. This feature, suggests that in chronic pain CNS activity in regions involved in cognitive processing differs between acute and chronic pain. These insights are further complicated by the new and revolutionary recognition that, in chronic pain, neuronal loss occurs in significant pain pathways including the thalamus and the lateral prefrontal cortex [34]. The role of this neurodegeneration in producing either the altered CNS responses or the pain state is not understood.
Maladaptative changes in non-sensory circuits may contribute to the psychological states, including depression, anxiety and amotivation that are often seen in these patients. Thus the study of specific brain regions such as The PAG is a 'core' structure in understanding how the brain modulates pain, both in placebo and in the effects of analgesics, particularly opioids. A number of regions have different functional components (e.g., amygdala, PAG) and the ability to dissect apart these within a set paradigm will contribute further to mechanistic functions of pain processing in humans.

Cortical Regions
Anterior Effects of pleasant and painful touch to hand. Oribitofrontal activation > pleasant or pain vs. neutral. SI less activated by pleasant and pain than neutral touch. Regional differences in aCG to pleasant (rostral aCG) and pain (posterior dorsal). Brainstem (e.g., PAG) activated by all 3 touch stimuli.
Clear dissociation between sensory and emotional systems to 'reward' and aversion.

Somatosensory Cortex Bingel et al., 2004 [66]
Painful laser stimuli applied to hand and foot produced somatotopic organization in contralateral and ipsilateral SI cortex.
Laser stimuli can provide stimuli without tactile components.  Heterotopic pressure stimulus applied to the thumb activates a number of brain regions.
Generalized increase in pain sensitivity in chronic pain; pain >> in patients than controls for the same pressure stimulus. Equally painful stimuli produced similar brain activations.

Spinal Cord Injury (SCI) Nicotra et al., 2005 [71]
Seven patients with SCI evaluated including painful stimuli (shock) in an aversive paradigm. Conditioning stimuli produces enhancement of activity in dorsal anterior cingulated, PAG and superior temporal gyrus to conditioning stimuli and attenuation in subgenual aCG, ventromedial prefrontal and posterior cingulated to threat of shock.
The study is able to dissect apart possible changes in the brains of SCI patients, including central sensitization and alterations in affective components of the brain (subgenual aCG) that may be part of a disturbance of affective and autonomic processing.
Unpleasant Odor Villemure et al., 2005 [72] Single patient with neuropathic pain where pain increased when exposed to experimental odors in thalamus, amygdala, aCG and SI.
This study may suggest subcortical mechanisms of aversion have a common neural circuitry.  the nucleus accumbens (involved in probability assessments and reward evaluation), the amygdala (involved in orientating to and the memory of motivationally salient stimuli), the hippocampus (involved in evaluating the expectancy of an unknown condition), the prefrontal cortex (involved in cognitive and planning functions around emotional stimuli or regarding rewarding or aversive outcomes) and the anterior cingulated cortex (involved in the rank ordering of the value or salience of the stimulus) may provide new insights into brain functioning in these comorbid conditions. Such insights should provide immediate benefits to the understanding of the calcitrant nature of chronic pain to therapeutic interventions.

Complex Regional Pain Syndrome
Our increased recognition that multiple neural systems are involved in pain processing and affect pain perception (reward/aversion circuitry, the role of anticipation, neural systems interpreting different pain types albeit at the same intensity, opponent systems and drug effects) suggests that multiple neural circuitries are likely affected in chronic pain. Results published thus far indicate that: (1) Pain intensity is probably not a good marker for changes in chronic pain state. Neural imaging may be able to define a correlation between CNS activation and patient answers to a simple subjective questionnaire that assesses emotional and other components of pain and suffering; (2) Neural systems interpreting components of the pain response (e.g., emotional, empathy, anticipation etc.) are clearly complex, and we still have no understanding of how these may change in the chronic pain condition; and (3) Standards will need to be applied across imaging facilities in order to interpret and compare data across studies.

fMRI of Human Surrogate Pain Models
Defining valid surrogate models has been a problem in both animal and human models of pain [35][36][37]. In human studies, mechanical (heat) or chemical (capsaicin) sensitization of skin and testing in primary and secondary regions affected has been used as a surrogate for neuropathic pain (hyperalgesia/allodynia to thermal and mechanical stimuli) [38]. Recently fMRI has been used to evaluate the capsaicin -induced hyperalgesia model (see Table 3). While many of these studies report increased activation in a number of brain regions, some of the more recent studies begin to define the utility of fMRI in dissecting mechanistic changes or insights using this model [39][40][41]. These studies demonstrate differences in brain activation in response to stimuli of equivalent pain intensity delivered in sensitized vs. non-sensitized state, providing further evidence that pain intensity by itself is probably not a useful measure of the status of the underlying pain processing circuitry [41]. An alternate explanation may be that there are mechanistic differences between these two states. Changes in perceived pain intensity may reflect acute changes in CNS sensory pathways but may not cor-relate with changes in CNS emotional pathways which may be relevant to an individuals' overall response to pain and may predict future pain conditions. Eventually, fMRI should allow the direct comparison of activation in specific CNS regions in experimental models with the activation seen in patients with neuropathic pain. Comparing such objective measures should allow us to determine where the model differs from the disease and to assess the validity of such models for evaluating potential therapies.

fMRI studies of Endogenous Analgesia
Endogenous modulatory networks can either facilitate or inhibit pain [42,43]. Endogenous analgesia refers to systems that produce the latter. These systems involve a network that includes higher cortical (e.g., anterior cingulate cortex) and subcortical regions (e.g., the amygdala, hypothalamus) that project to brainstem nuclei (periaqueductal gray and raphe nuclei) that send projections to the dorsal horn [44] These systems can be modulated by a number of factors including stress, pain and the placebo response [42].
A number of studies have used fMRI to investigate endogenous modulation of pain (Table 4) and map circuits involved in CNS systems that can alter decrease or increase pain [45][46][47]. Most of these studies involved attention or distraction to modulate circuits. In addition, closely linked with this are studies of placebo response, evaluation of the effects of attention and expectancy, of empathetic reactions to pain in others, to producing "trickery" of the brain by sensory inputs [48].
Perhaps of greatest importance are studies of the placebo effect since there has been a significant literature in this domain from psychophysical studies [49,50]. A neurobiology and neurocircuitry were predicted for the placebo effect based on its effects on analgesia. [51]. Indeed the general circuitry of the placebo response can be applied to non-painful stimuli. These and other studies have enhanced our knowledge of the interaction of physiological pain circuits and cognitive/emotional circuits [52]. The use of imaging has now clearly established how some of these endogenous systems operate. This understanding coupled with an objective method of evaluating placebo should provide novel insights into drug development as well as the treatment of patients with acute and chronic pain.
Complementary with fMRI studies on placebo, the use of fMRI has identified neural systems involved in anxiety and fear related to pain. These two reactions to pain are important both from a neuroscience aspect.
[16] as well as from practical applications of treating patients. While fear and anxiety have been considered to have different effects on neural processing [53], recent fMRI studies have begun to explore this issue [54].
The innate nature of the pain experience is clearly indicated by studies showing that activations in non-sensory CNS systems in an observer experiencing empathetic pain, are similar to those produced in a subject by noxious stimuli. The study of endogenous analgesia highlights the opponent systems operating in pain. In addition, fMRI studies reveal that in addition to the sensory pathways activated in endogenous analgesia and pain processing, reward/aversion circuitry is activated, with reward related to pain relief and aversion related to pain.
[21]. The balance between these opponent systems may be crucial in determining the overall sensory and emotional experience of pain in chronic pain states.
fMRI has also been applied to exploring the neurobiology of acupuncture, which is believed to activate endogenous analgesic mechanisms [55]. Such studies have predominantly been in healthy subjects using experimental pain. The evidence for the benefit of acupuncture for clinical studies has been mixed. For example, recent studies in migraine patients has indicated that acupuncture may be no more effective than sham acupuncture in reducing migraine headaches, although both are more effective than no intervention. Such studies need to be repeated, but raise questions as to how acupuncture works (for example, through activation of diffuse noxious inhibitory controls or activation of endogenous systems through expectancy etc.) [56]. In carefully devised studies, defining brain circuits involved in expectancy, treatment etc. may help provide a more objective evaluation of such interventions.

fMRI Studies of Analgesics
fMRI is also being applied to the evaluation of analgesics (pharmacological MRI or phMRI). [57]. Examples are provided in Table 5.
Analgesic effects on brain systems or neural circuits (stimulus independent) -Many analgesics have direct CNS effects, and very little is known about how they act on the human brain. Such studies are most often performed in healthy volunteers. Here the direct effect of administration of a drug is observed without any stimulus paradigm.  Table 3:

Definitions of terms in
Allodynia -pain to a normally non-noxious stimulus. Central Sensitization -increased sensitivity or excitability in central pain pathways as a result of increase in sensitivity/activation of these neural systems Hyperalgesia -An increased response to a stimulus that is normally painful Secondary Hyperalgesia -pain outside of the area of the primary injury. Placebo is a process in reward processing.
Placebo analgesia Bingel et al., 2006 [85] Nineteen healthy subjects. Placebo analgesia using laser for pain stimulation shows interaction between aCG, amygdala and PAG Interactions between emotional circuits including the aCG amygdala and affect output processing of endogenous pain control mechanisms.

Attention
Attentional modulation Tracey et al., 2002 [46] Nine Subjects. Distraction during painful thermal stimulus. Pain ratings significantly lower with distraction with increased activation in the PAG during this condition.
Specific output of modulatory system via a well-known brain region (i.e., PAG) presumably via inputs from higher cortical regions.
Distraction Valet et al., 2004 [47] Stroop task used for distraction during noxious and innocuous heat stimuli. Distraction produced decreases in VAS pain intensity and unpleasantness scores. Distraction increased activation in orbitofrontal cortex, perigenual aCG, PAG and posterior thalamus.
Covariate analysis indicated that the brain may gate information by exerting a top-down effect on PAG and posterior thalamus. Distraction has not been used in fMRI studies of chronic pain.
Attention to 'location' and 'unpleasantness' Kulkarni et al., 2005 [88] Attention to location -activity in SI and inferior parietal cortex. Attention to unpleasantness -activation reported in aCG, orbitofrontal and frontal cortex, amygdala, hypothalamus and Study focus is on how attention can significantly modulate pain processing.

Miscellaneous
Empathy pain activates affective but not sensory pain Singer et al., 2004. [89] Empathy evaluated by subject in magnet observing loved one receive similar painful stimulus (empathetic pain). Activation in insular, aCG, brainstem and cerebellum by both direct or empathetic pain.
Activation in affective circuits not sensory -this may be further support for affective circuits being a focus of study in chronic pain. Basal ganglia play a role in sustained salience.

Expectancy orAnticipation
Dissociation of pain from its anticipation Ploghaus et al., 1999 [27] Expectation of pain produced activation in medial frontal region, insula, and cerebellum. These differed from pain experience.
Emotional/cognitive evaluation of a situation can produce adaptation that can modify the experience. This has enormous implications in the clinical situation e.g., anticipating a procedure. Effects in or on chronic pain are unknown.

Expectation of Pain Sawamoto et al., 2000 [92]
Expectation increases response to non-painful stimuli in the aCG and posterior insula.
Pain/unpleasantness and pain relief may be opponent processing using similar circuitry. HI pain produced activation in thalamus, aCG, I, prefrontal and parietal cortices.
Pain pathways can be activated without a noxious stimulus. This has implications for understanding CNS processing in chronic pain disorders with no specific etiology.
Expectancy using a conditioning cue Keltner et al,. 2006 [45] Pain intensity expectancy acts via a modulatory network that converges on the nucleus cuneiformis (nCF) A study defining a specific modulatory pathway on this brainstem nucleus.

Paradoxical Sensations
Paradoxical heat Davis et al., 2004. [48] When subjects perceived a painful stimulus even though the stimulus was cool or neutral, activation in the right insular cortex was observed.
Sensory inputs in the normal healthy condition can "confuse" the brain. Such insights will be helpful in understanding pain processing in chronic conditions, particularly neuropathic pain.
Definition of the utility of percept-related fMRI -i.e., importance of on-line measures of psychophysical data.
Mailis-Gagnon et al., 2003 [96] Noxious and non-noxious stimuli were not perceived in these dermatomes (Perceived stimuli activated posterior region of the aCG, thalamus); but produced decreased signal changes in a number of cortical regions (SI, SII, parietal cortex, prefrontal cortex and rostral aCG).
Four Patients tested to evaluate nondermatomal neurosensory deficits. Another insight into evaluating complex patient groups with altered pain processing. fMRI however does provide data in support of a testable neurobiological hypothesis instead of generic labeling of such patients.
Difficult studies because good controls are so difficult. Process of activation of limbic and paralimbic structures may nevertheless be highly important in the therapeutic effect in clinical conditions. Activation of PAG Liu et al., 2004 [98] Mechanical stimulation produced activation in PAG after 20+ min of stimulation.
Activation of endogenous analgesic systems may be part of underlying effects of acupuncture. Real time fMRI (rtfMRI) to train subjects to control activation in rACC. Subjects (control and chronic pain) could change activation in ACC with corresponding change in perception to noxious stimuli First use of rtfMRI in pain.  First study on opioids to address direct CNS effects. Naloxone is a drug that has no cognitive effects in normal healthy volunteers.
fMRI of the effects of morphine on CNS circuits -indicating the use of this approach to define specific circuitry activated by a drug.

Antiseizure meds
Gabapentin Ianetti et al., 2005 [41] Healthy volunteers. In a capsaicin model, single dose gabapentin has an antinociceptive effect but a stronger antihyperalgesic effect: the study indicates that the drug is more effective in the sensitized state.
An excellent example of the application of fMRI to drug evaluation in dissecting the value of a model with potential clinical relevance. These types of studies allow for the interrogation of effects that may not be obvious (e.g., subcortical, subconscious), for integration of how drugs may have a role on intact brain systems that still may be the case in the chronic pain state, and for the evaluation of potential side effects of drugs. Our naloxone and morphine studies (see Table 4; [58,59]) have taken this approach and indicate the ability to evaluate direct drug effects even when there are no obvious psychophysical effects (naloxone) or welldescribed side effect profiles (morphine) that can be evaluated based on circuit activation (e.g., reward, sedation or analgesic circuits). [59]. The ability to define specific differences across classes of drugs (e.g., antidepressants, membrane stabilizers, opioids) may not only help focus on common areas of potential mechanisms but also provide information within different drug classes (e.g., antidepressants -tricyclics vs. serotonin norepinehprine reuptake inhibitors). Advances in this domain should lead to use of standardized fMRI trials for early phase evaluation of pharmacotherapies for pain [60].

Anti-inflammatory
Analgesic effects on acute or chronic pain (stimulusdependent) -In this group, the effect of the drug is evaluated in subjects usually following an applied painful stimulus.
A few examples of this type of approach include the studies of cyclooxygenase (cox) inhibitors [61] and amitriptyline [62] in chronic pain conditions and the effects of drugs on capsaicin-induced hyperalgesia (see Table 5). These approaches show that pharmacological evaluation of the CNS effects of drugs is possible, suggesting that fMRI can be used for objective assessments of drug efficacy; until now, all assessments of analgesic efficacy relied on subjective psychophysical measures.

Conclusion
A revolution in the application of a relatively new technology, fMRI, to the field of pain and analgesia is upon us. Within the next half decade, we should begin to see direct benefits in the clinical setting that could range from (a) use of fMRI to evaluate/diagnose a pain condition; (b) use of fMRI to evaluate drug efficacy in responders vs. nonresponders; (c) use of fMRI to evaluate novel drug efficacy (the latter will be driven predominantly by the pharmaceutical industry) and (d) use of fMRI to provide new insights into the mechanisms of endogenous 'pain systems'. We believe there is good reason to expect that the contribution of this technology together with advances in other neurosciences will help transition the state of current pain therapy from 'o me miserum!' ('o woe is me!') to more optimistic states for both patient and clinician 'semper aliqud novii' ('always something new' .... and better/useful). We believe there is good reason to expect that the contribution of this technology together with advances in other neurosciences will significantly advance therapies for chronic pain and alleviate physical and emo-tional suffering for the many individuals living with this disease.